(Q57579888)

English

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort

scientific article published on 20 March 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Vladimir Semiglazov

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

author name string

Wolfgang Eiermann

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Sergei Tjulandin

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Milvia Zambetti

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Angela Moliterni

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Federico Vazquez

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Mikhail J Byakhov

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Mikhail Lichinitser

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Miguel Angel Climent

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Belen Ojeda

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Mauro Mansutti

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Alla Bozhok

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Domenico Magazzù

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Dominik Heinzmann

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Jutta Steinseifer

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Pinuccia Valagussa

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Jose Baselga

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

publication date

20 March 2014

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

640-647

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970080-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970080-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant trastuzumab in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970080-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970080-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970080-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970080-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970080-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970080-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970080-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Making sense of clinical trial data: is inverse probability of censoring weighted analysis the answer to crossover bias?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970080-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970080-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970080-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970080-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathological complete response and accelerated drug approval in early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970080-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970080-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970080-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970080-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(14)70080-4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24657003%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57579888&oldid=2032404207"